By Benjamin Chiou
Date: Friday 22 Nov 2024
(Sharecast News) - Biopharma giant GSK has announced that Japanese regulators have expanded the approved use of its Arexvy vaccine for severe respiratory syncytial virus (RSV) disease to a wider age range.
Director Holdings | 22-Nov-2024 | 08:30 | RNS |
Japan approves first RSV vaccine for adults 50-59 | 22-Nov-2024 | 07:00 | RNS |
IRB Approval for Phase I Clinical Trial | 22-Nov-2024 | 07:00 | RNS |
Inaphaea award of HEIF Funding and PhD sponsorship | 22-Nov-2024 | 07:00 | RNS |
Indivior to Participate in Upcoming Investor Event | 22-Nov-2024 | 07:00 | RNS |
Questor :GW Pharmaceuticals | 04-Dec-2014 | Telegraph |
Questor : Hikma Pharmaceuticals | 13-Mar-2014 | Telegraph |
Investment Column:BTG | 06-Oct-2011 | The Independent |
Investment Column:Genus | 09-Sep-2011 | The Independent |
Questor :Dechra Pharmaceuticals | 08-Sep-2011 | Telegraph |
Price | 19,430.33 |
Closing Price Change | 171.19 |
% Change | 0.89 % |
21-Nov-24 Close | 19,430.33 |
You are here: research